Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Clinical trial NCT05418088 · RECRUITING

Trial details

NCT number: NCT05418088
Sponsor: Sumithira Vasu
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Acute Lymphoblastic Leukemia Recurrent B Acute Lymphoblastic Leukemia Recurrent B-Cell Prolymphocytic Leukemia Recurrent Chronic Lymphocytic Leukemia Recurrent High Grade B-Cell Lymphoma Recurrent Indolent Non-Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Transformed Chronic Lymphocytic Leukemia Refractory Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia Refractory B-Cell Prolymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia

Start date: 2022-06-30
Primary completion: 2027-07-01
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.